GlassScriptPhysician profile
Gretchen D Shull
NPI 1689621336
$5,319.29
in general payments reported to CMS, 2019-2025
30 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $175 · 2021: $30.75 · 2022: $1,648 · 2023: $780 · 2024: $573 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,443.65 | 2022-2023 | Tepezza |
| Novo Nordisk INC | $967.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $475.72 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $334.83 | 2020-2025 | Freestyle Libre |
| Amgen INC. | $315.75 | 2019-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.49 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $196.45 | 2022-2025 | |
| Cequr Corporation | $130.91 | 2023-2024 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $125.14 | 2023-2025 | |
| Radius Health, INC. | $124.63 | 2020-2025 | Tymlos |
| Antares Pharma, INC. | $117.59 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals LP | $116.31 | 2021-2024 | Farxiga |
| Insulet Corporation | $96.21 | 2022-2023 | Omnipod |
| Lilly USA, LLC | $94.86 | 2019-2025 | Zepbound, Mounjaro |
| Tandem Diabetes Care, INC. | $92.29 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $66.81 | 2024-2025 | Yorvipath |
| Medtronic, INC. | $63.35 | 2023-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $60.71 | 2023-2024 | |
| Beta Bionics, INC. | $54.03 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Neurocrine Biosciences, INC. | $45.59 | 2025 | |
| Abbvie INC. | $39.80 | 2025 | |
| Valeritas, INC. | $28.12 | 2019 | |
| Sequel Med Tech, LLC | $18.91 | 2025 | Twiist |
| Kyowa Kirin, INC. | $16.50 | 2025 | |
| Shire North American Group INC | $16.19 | 2019 | |
| Medtronic Minimed, INC. | $14.55 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.88 | 2025 | Unithroid |
| Merck Sharp & Dohme LLC | $12.33 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.52 | 2019 | |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretchen Shull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.